Current stock page

Stock Analysis

Jazz Pharmaceuticals plc (JAZZ) Stock Analysis

Jazz Pharmaceuticals plc (JAZZ) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

JAZZ Stock Analysis Summary

Jazz Pharmaceuticals plc (JAZZ) currently has an AIQ Score of 73/100, indicating a bullish setup. Value is the strongest factor at 79/100. Momentum is the weakest current factor at 66/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

JAZZ at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$241.55
AIQ Score73/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$15.63B
P/E Ratio (TTM)67.47
Forward P/E—
EPS (Q3 FY2026)-$7.48
Revenue (Q3 FY2026)$1.24B
Dividend Yield (TTM)0.00%
Beta0.58
Volume496.7K
52-week range$136.56-$266.38
RSI 1460.77
50-Day SMA$229.13
200-Day SMA$220.03
Analyst Price Target$297.36
Next EarningsFeb 23, 2027
As of Nov 13, 2026 · Market close

JAZZJazz Pharmaceuticals plc

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$241.55+$1.18 (+0.49%)

Latest quote

  • Momentum
    66
  • Value
    79
  • Quality
    76
  • Risk resilience
    73
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

JAZZ Stock Analysis Summary

Jazz Pharmaceuticals plc (JAZZ) currently has an AIQ Score of 73/100, indicating a bullish setup. Value is the strongest factor at 79/100. Momentum is the weakest current factor at 66/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, JAZZ has AIQ Score of 73/100 with Value base of 79/100 and fading Momentum at 66/100. Wait for component alignment before adding exposure.

Healthcare · 0.49% stock move · JAZZ classified in Biotechnology.

Current Evidence

BullishJAZZ is in a bullish AIQ regime; Value is the strongest visible factor at 79/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is JAZZ Bullish or Bearish Right Now?

JAZZ currently has a bullish overall setup. Value is the strongest factor at 79/100, while Momentum is weakest at 66/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 76/100.
  • - Momentum is constructive at 66/100.
  • - Risk Resilience is supportive at 73/100.
  • - Price is +5.42% above its 50-day SMA.
  • - Analyst target implies +23.11% upside from the latest quote.
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

JAZZ's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 4 neutral, and 6 sell votes. JAZZ's 14-day RSI is 60.77, which places the stock in a constructive momentum range. JAZZ's beta is 0.58, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in JAZZ?

The largest recent change in JAZZ is Momentum moving up by 7.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+7.0
Quality
+0.0
Risk
-1.0

What Would Change the JAZZ Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

JAZZ Decision Framework

Public evidence layers, setup checks, and risk context for Jazz Pharmaceuticals plc.

Jazz Pharmaceuticals plc (JAZZ) Stock Analysis

Jazz Pharmaceuticals plc has an AIQ Score of 73/100 in a Bullish regime. Value is strongest at 79/100. Beta is 0.58, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextJAZZ is in a Bullish AIQ regime with score 73/100.
Signal ConflictThe primary conflict is that value leads at 79/100 while momentum lags at 66/100.
Factor EvidenceMomentum 66/100 · Value 79/100 · Quality 76/100 · Risk 73/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Value is the strongest factor at 79/100.

TimingPass

Momentum is 66/100 and RSI (14) is 60.8.

Regime fitPass

JAZZ is in a Bullish regime at 73/100.

Risk controlPass

Risk factor is 73/100 with beta 0.58 and annual volatility 38.64%.

ConflictPass

Current conflict: value leads at 79/100 while momentum lags at 66/100.

AIQ Score
73/100
Price
$241.55
Beta
0.58
RSI (14)
60.8

JAZZ Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

JAZZ Fundamentals

JAZZ valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$1.24B
Net income
-$483.4M
Free cash flow
$489.9M
View full JAZZ fundamental analysis

JAZZ Technical Analysis

JAZZ technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
60.77
Price vs SMA-50
+5.42%
View full JAZZ technical analysis

JAZZ Stock Catalysts

Track JAZZ earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 23, 2027
Analyst target
$297.36
News items
5
View JAZZ earnings and stock catalysts

JAZZ Dividend Analysis

JAZZ dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View JAZZ dividend history and analysis

JAZZ Financial Data

JAZZ revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$1.24B
EPS
-$7.48
Periods
8
View JAZZ financials

JAZZ Risk Analysis

JAZZ volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.58
Risk score
73/100
1Y volatility
38.64%
View JAZZ risk analysis

JAZZ Stock News

JAZZ stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read JAZZ stock news

JAZZ vs Biotechnology Peers

Current peer cohort: JAZZ · KOD · KRYS · KURA · KYMR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
JAZZ
Current stock
73/10079/10066/10073/1001.4738.64%Current
KOD
Kodiak Sciences Inc.
52/100—91/10044/1001.43205.61%JAZZ vs KOD
KRYS
Krystal Biotech, Inc.
69/10067/10058/10069/1001.1639.38%JAZZ vs KRYS
KURA
Kura Oncology, Inc.
47/10070/10040/10039/100-0.2563.01%JAZZ vs KURA
KYMR
Kymera Therapeutics, Inc.
65/10043/10087/10060/1001.3363.12%JAZZ vs KYMR
Pairwise Compare links: KOD · KRYS · KURA · KYMRJAZZ vs KODJAZZ vs KRYSJAZZ vs KURAJAZZ vs KYMRCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a JAZZ stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for JAZZ: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
67.47
As of Nov 13, 2026
Revenue growth
10.38%
Gross margin
88.17%
Current debt / equity
1.35
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$1.24B
Quarter net income
-$483.4M
Quarter free cash flow
$489.9M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
60.77
MACD
5.24

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
73/100
Beta
0.58
Annual volatility
38.64%
Max drawdown
-21.62%

JAZZ Stock FAQ

What is JAZZ stock price today?

Jazz Pharmaceuticals plc's current stock price is $241.55. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is JAZZ bullish or bearish right now?

JAZZ's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is JAZZ's market cap?

JAZZ's market cap is $15.63B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is JAZZ's current P/E ratio?

JAZZ's current P/E ratio is 67.47 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is JAZZ's RSI?

JAZZ's 14-day RSI is 60.77 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is JAZZ above its 50-day and 200-day moving averages?

JAZZ is 5.42% from its 50-day SMA and 9.78% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is JAZZ's next earnings date?

JAZZ's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does JAZZ pay a dividend?

JAZZ's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.